Kilder

Benfari G, Antoine C, Miller WL et al. Excess Mortality Associated With Functional Tricuspid Regurgitation Complicating Heart Failure With Reduced Ejection Fraction. Circulation. 2019;140(3):196-206. 

Broch K, Urheim S, Lønnebakken MT et al. Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. Heart. 2016;102(3):191-7. 

Connolly SJ, Karthikeyan G, Ntsekhe M et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022;387(11):978-988. 

Gheorghe GS, Hodorogea AS, Gheorghe ACD et al. Medical management of symptomatic severe aortic stenosis in patients non-eligible for transcatheter aortic valve implantation. J Geriatr Cardiol. 2020;17(11):704-709. 

Lacro RV, Dietz HC, Sleeper LA et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371(22):2061-71. 

Laenens D, Stassen J, Galloo X et al. The impact of atrial fibrillation on prognosis in aortic stenosis. European Heart Journal - Quality of Care and Clinical Outcomes. 2023;9, 778–784. 

Rossebø AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. Engl J Med. 2008; 359: 1343–1356. 

Taramasso M, Benfari G, van der Bijl P et al. Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation. J Am Coll Cardiol. 2019;74(24):2998-3008. 

Vahanian A, Beyersdorf F, Praz F et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632.